Molecular Pathways: PI3K Pathway Phosphatases as Biomarkers for Cancer Prognosis and Therapy

摘要: Cancer research has seen tremendous changes over the past decade. Fast progress in sequencing technology afforded us with landmark genetic alterations, which had immediate impact on clinical science and practice by pointing to new kinase targets, such as phosphoinositide 3-kinase (PI3K), EGF receptor, or BRAF. The PI3K pathway for growth control emerged a prime example both oncogene activation tumor suppressor loss cancer. Here, we discuss how therapy using inhibitors could benefit from information specific phosphatases, naturally antagonize targets. This is found mutated most cancer types, including prostate, breast, colon, brain tumors. tumor-suppressing phosphatases operate at two levels. Lipid-level PTEN INPP4B, revert activity keep lipid second messengers inactive. At protein level, PHLPP1/2 inactivate AKT kinase, thus antagonizing mTOR complex 2 activity. However, contrast their counterparts are unlikely drug They would need be stimulated commonly deleted Yet, because they occupy critical nodes preventing initiation progression, status potential outcome prediction, matching available inhibitor repertoire right patients. Clin Res; 20(12); 3057–63. ©2014 AACR .